Meredith E. Davis-Gardner

Centers for Disease Control and Prevention — United States

Medicine · Health Sciences

31h-index4.2kcitations77works10.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(46), COVID-19 Clinical Research Studies(22), Monoclonal and Polyclonal Antibodies Research(13), Immunotherapy and Immune Responses(11), SARS-CoV-2 detection and testing(11)

Publications77 total

The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant
The Lancet Infectious Diseases·2025· 10 cited
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Journal of Virology·2024· 7 citedOpen Access
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Nature Immunology·2024· 33 citedOpen Access
CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
Science Advances·2024· 16 citedOpen Access
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Science Translational Medicine·2024· 14 citedOpen Access
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection
UNC Libraries·2024Open Access
Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Research Square (Research Square)·2024· 3 citedOpen Access
CD4+ and CD8+ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
2024· 2 citedOpen Access
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Nature·2023· 86 citedOpen Access
Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates
2023· 4 citedOpen Access
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
npj Vaccines·2023· 5 citedOpen Access
Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates
2023· 9 citedOpen Access
Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
2023· 4 citedOpen Access
A wild boar cathelicidin peptide derivative inhibits severe acute respiratory syndrome coronavirus-2 and its drifted variants
Scientific Reports·2023· 1 citedOpen Access
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates
Science Immunology·2023· 28 citedOpen Access
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Structure·2023· 7 citedOpen Access
A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
Frontiers in Immunology·2023· 11 citedOpen Access
Durability of immune responses to mRNA booster vaccination against COVID-19
Journal of Clinical Investigation·2023· 87 citedOpen Access
High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2
SLAS DISCOVERY·2023· 14 citedOpen Access
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
New England Journal of Medicine·2022· 265 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Mehul S. Suthar(28), Lilin Lai(16), Daniel C. Douek(12), Michael Farzan(11), Katharine Floyd(10), Sucheta Godbole(10), Amy R. Henry(9), Venkata Viswanadh Edara(9), Jens Wrammert(8), Michaela U. Gack(8), Nadine Rouphael(8), Matthew R. Gardner(8), Grace Mantus(7), Kelly E. Manning(7), Madison Ellis(7), Pei‐Yong Shi(6), Lindsay E. Nyhoff(6), Rafi Ahmed(6), Eli Boritz(5), Matthew Gagné(5)